BOSTON, Jan. 08, 2026 -- Aktis Oncology, Inc. (“Aktis”), a clinical-stage oncology company focused on expanding the breakthrough potential of targeted radiopharmaceuticals to large patient populations, including those not addressed...
Dynogen Pharma gets $50M round (TheDeal.com)
News | 04. 19. 2004
Dynogen Pharmaceuticals
Boston-based Dynogen Pharmaceuticals Inc. said Monday, April 19, it had secured a $50 million B round of financing that it will use to further develop its neuroscientific approach to treating genitourinary and gastrointestinal disorders.
